Stockwinners Market Radar for March 10, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:18 EST Yum China says SEC to prohibit securities of issuers under HFCAA - Yum China provided an update on its status under the Holding Foreign Companies Accountable Act. On March 8, 2022, as expected in its implementation of the Act, the U.S. Securities and Exchange Commission provisionally named the Company as a Commission-Identified Issuer, following the Company's filing of its annual report on Form 10-K with the SEC on February 28, 2022. The SEC estimated that 273 registrants might be identified under the Act as part of its review of registrants in calendar year 2020, and Yum China previously disclosed that it expected to be so identified. The identification is pursuant to the Act, which requires the SEC to prohibit the securities of any "covered issuer," including the Company, from being traded on any of the U.S. securities exchanges, including the New York Stock Exchange, if the auditor of the covered issuer's financial statements is not subject to inspection by the U.S. Public Company Accounting Oversight Board for three consecutive years, beginning in 2021. Under the current terms of the Act, the Company's common stock will be delisted from the New York Stock Exchange in early 2024, unless the Act is amended to exclude the Company or the PCAOB is able to conduct a full inspection of the Company's auditor during the required timeframe. The Company's common stock trades on the New York Stock Exchange and, on September 10, 2020, the Company completed a secondary listing of its common stock on the Main Board of the Hong Kong Stock Exchange under the stock code "9987". The shares listed on the HKEX are fully fungible with the shares listed on the NYSE. The Company will continue to monitor market developments and evaluate all strategic options.

19:15 EST SeaWorld announces replenishment of share repurchase program - SeaWorld Entertainment announced that its Board of Directors approved a replenishment of $228.2M to the company's previously authorized share repurchase program, bringing the total amount authorized for future share repurchases back up to $250M. Under the Share Repurchase Program, the company is authorized to repurchase shares through open market purchases, privately-negotiated transactions or otherwise in accordance with applicable federal securities laws, including through Rule 10b5-1 trading plans and under Rule 10b-18 of the Exchange Act. The Share Repurchase Program has no time limit and may be suspended or discontinued completely at any time. The number of shares to be purchased and the timing of purchases will be based on the company's trading windows and available liquidity, general business and market conditions, and other factors, including legal requirements, debt covenant restrictions and alternative investment opportunities.

18:54 EST AMC Entertainment SVP Connor sells 50,000 class A shares - In a regulatory filing, AMC Entertainment senior VP, General Counsel, and Secretary Kevin Connor disclosed the sale of 50,000 class A common shares of the company on March 8 at a price of $15.049 per share.

18:13 EST GreenOaks Capital reports 13.0% passive stake in Samsara - GreenOaks Capital disclosed a 13% stake in Samsara, which represents over 5.0M shares. The filing does not allow for activism. Samsara shares are up 3.9% afterhours at $17.50.

18:05 EST Copa Holdings reports preliminary February traffic down 13% vs. 2019 - Consolidated capacity came in 9.8% lower than February 2019, while passenger traffic decreased 13.0%, which resulted in an 80.7% load factor.

17:42 EST Guaranty Bancshares increases dividend 10% to 22c per share - Guaranty Bancshares declared a quarterly cash dividend on March 9 in the amount of 22c per share of common stock. This is a 10% increase in the quarterly cash dividend and will be paid on April 13 to stockholders of record as of the close of business on March 28.

17:35 EST Oracle sees FY22 operating margin 1%-2% higher than pre-pandemic levels of 44%

17:01 EST McEwen Mining sees 2022 production 153,000-172,000 au eq. oz. - McEwen Mining provided production and cost guidance for 2022. Estimates production of 153,000-172,000 gold equivalent ounces - GEOs - in 2022. Cash costs and all-in sustaining costs per GEO sold for 2022 from 100%-owned mines - Gold Bar and Fox - are expected to be $1,310-1,410 and $1,570-1,690, respectively. At San Jose, production is estimated to be 69,500-77,500 GEOs at an AISC per GEO sold of $1,330-1,370.

16:53 EST Rivian Automotive drops 14% to $35.19 after Q4 results miss estimates

16:48 EST FedEx Express President, CEO Donald Colleran to retire, Richard Smith to succeed - FedEx Corp. announced that Donald Colleran, president and CEO, FedEx Express, will retire effective Dec. 31, 2022, after a distinguished nearly 40-year career at FedEx. Richard Smith, regional president of the Americas and executive vice president of global support, will succeed Colleran as president and CEO of FedEx Express. Richard Smith will become president and CEO-elect of FedEx Express on April 1, and will assume full duties on Sept. 1. Colleran will remain at FedEx Express as the CEO Executive Advisor through the end of December to help ensure a smooth transition of responsibilities. Smith joined FedEx in 2005. He previously served as the president and CEO of FedEx Logistics, and in a series of leadership positions in life sciences, healthcare, and customer solutions, including serving as vice president of global trade services and managing director of life sciences and specialty services.

16:45 EST PlayAGS sees year-end 2022 net leverage target of less than 4.0x - The company said, "Supported by our strong finish to 2021, the approximately $10 million of annualized cash interest expense savings we expect to realize in conjunction with our recent debt refinancing and the operating momentum we continue to see in the business, we remain confident in our ability to deliver upon our previously issued year-end 2022 net leverage target of less than 4.0x."

16:39 EST T-Mobile to offer new iPhone SE, iPad Air with 5G on March 18th - The company states: "T-Mobile will offer the powerful iPhone SE with exceptional capabilities and performance at an incredible price, sophisticated alpine green iPhone 13 Pro and stunning green iPhone 13, and the powerful and versatile iPad Air with the breakthrough M1 chip. iPhone SE comes in a compact and durable design, and together with iOS 15, delivers a seamless experience. The new iPhone SE features impressive upgrades, including the performance of A15 Bionic, unlocking advanced camera capabilities, and makes nearly every experience better, from photo editing to power-intensive operations like gaming and augmented reality."

16:37 EST Rivian eyes ways to further expand commercial partnership with Amazon - "At the end of 2021, we sold the first production EDV to Amazon (AMZN)," Rivian (RIVN) said. "Since then, we have continued production at our plant. The bring up of our manufacturing lines for the EDV has been smoother than R1T or R1S as these lines benefited from the collective learnings from our R1 line. While the line ramp has been positive, the ramp of production has largely been gated by a number of supplier constraints. Our team has been incredibly focused on working with these suppliers to achieve our needed ramp. During this time, we have also been working in close partnership with Amazon to refine the digital integration of the EDV as well as our software platform to support the most effective operation of the vehicles. We intend to scale production and deployments in the second quarter of this year. As we progress through these significant milestones, we are also in the process of exploring ways to further expand our commercial partnership with Amazon."

16:36 EST Victory Capital reports total AUM $176.0B on February 28, 2021 vs. $176.8B m/m

16:34 EST Peloton names Andrew Rendich as Chief Supply Chain Officer, effective March 16 - Peloton announced that Andrew Rendich will be joining the company as Chief Supply Chain Officer, effective March 16, and Shari Eaton, currently Senior Vice President, Global Head of People, has been promoted to Chief People Officer. Rendich previously served as COO at Grove Collaborative.

16:32 EST Luxfer raises quarterly dividend by 4% to 13c per share - The next quarterly dividend is payable on May 4, 2022, to shareholders of record on April 14, 2022.

16:31 EST InfiniteWorld names Milica Zec chief metaverse officer - Infinite Assets announced the company has added Milica Zec to its executive team as Chief Metaverse Officer. Zec will lead the company's metaverse initiatives, including current and upcoming projects and partnerships for brand development. Prior to joining InfiniteWorld, Zec co-founded New Reality Company where she served as Producer and Director, Mixed Reality & Metaverse. At New Reality, she assembled and led dozens of teams of up to 100+ people in the creation, marketing, audience building and fundraising of projects in multiple industries and media. "We are very pleased for Milica to join the InfiniteWorld team in this important role," said InfiniteWorld CEO Yonathan Lapchik. "Milica brings a tremendous level of leadership, innovation and expertise in the metaverse to the company. Her impressive experience will have a significant impact on our company as we move forward."

16:24 EST Manning & Napier reports preliminary AUM $20.8B as of February 28 - Compared with $21.4B at January 31, 2022 and $22.5B at December 31, 2021.

16:19 EST Oracle drops 6% to $71.76 following Q3 EPS miss

16:18 EST AudioEye acquires The Bureau of Internet Accessibility, terms not disclosed - AudioEye announced it has acquired The Bureau of Internet Accessibility, an automated testing platform combined with a step-by-step guide for website owners and developers to fix accessibility issues. The acquisition is another positive step in AudioEye's ongoing mission to eradicate all barriers to digital accessibility. Following the acquisition, BoIA's staff will join AudioEye.

16:11 EST American Outdoor Brands to acquire Grilla Grills for $27M in cash - American Outdoor Brands announced that it has entered into an agreement to acquire privately owned Grilla Grills, a provider of high-quality, barbecue grills, Wi-Fi-enabled wood pellet grills, smokers, accessories, and modular outdoor kitchens for $27M in cash, or approximately $24M after factoring in the future tax benefit resulting from the asset purchase. The acquisition of Grilla will allow American Outdoor Brands to enter the estimated $7B, U.S. barbecue grill market with an authentic, direct-to-consumer brand that can benefit from the company's Dock & Unlock strategy and drive growth in the company's outdoor lifestyle product category. American Outdoor Brands negotiated directly with the seller on the transaction, which will be structured as an asset acquisition, and is expected to be immediately accretive to American Outdoor Brands net sales and non-GAAP net income. The transaction is expected to be completed in the coming days, following the satisfaction of customary closing conditions. American Outdoor Brands expects to fund the acquisition utilizing a combination of cash on hand and availability from the company's existing line of credit. In conjunction with the asset acquisition, TD Bank has approved an amendment to the company's current Loan and Security Agreement, increasing the capacity on the revolving line of credit from $50M to $75M, with no change to the existing $15M accordion feature. The amendment is expected to close within the next two weeks.

16:09 EST Oracle CEO says 'strong top line growth' in Q3 - "In Q3, Oracle delivered over 7% constant currency revenue growth-our highest quarterly organic revenue growth rate since we began our transition to the cloud," said Oracle CEO, Safra Catz. "This strong top line growth was coupled with a solid non-GAAP constant currency operating profit growth of 4%, but the big story is that our overall revenue growth is being driven by both our rapidly growing Cloud Infrastructure and Cloud Applications businesses. Q3 Cloud Infrastructure revenue was up 47% in constant currency. Q3 Cloud Applications growth was led by Fusion ERP, which was up 35% in constant currency and NetSuite ERP which was up 29% in constant currency. Total Cloud revenue which includes Cloud Infrastructure and Cloud Applications is now over $11 billion a year." "In Q3, Oracle completed development of the multi-cloud version of our MySQL HeatWave open-source database," said Oracle Chairman and CTO, Larry Ellison. "The MySQL HeatWave database is already running in the Oracle Gen2 Cloud. In a few weeks, MySQL HeatWave will also be available in the Amazon Cloud and the Microsoft Azure Cloud. MySQL HeatWave was designed to compete with Amazon's version of MySQL called Aurora, Snowflake and other popular cloud databases. What customer and database analysts are saying about Oracle's new MySQL HeatWave database is simply astonishing. Here are a couple of examples of what the database analysts are saying."

16:08 EST Oracle reports short-term deferred revenues $7.9B - Operating cash flow was $10.4B during the trailing twelve months.

16:07 EST Red Robin sees FY22 adjusted EBITDA $80M-$90M - Sees FY22 CAPEX $40M-$50M.

16:04 EST LegalZoom board approves $150M share repurchase program - The company's board approved a share repurchase program authorizing us to repurchase up to $150M of common stock. Stock repurchases under this program may be made in any manner, including through open market transactions, accelerated share repurchase agreements, or privately negotiated transactions with third parties, and in such amounts as management deems appropriate. The timing and actual amount of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, alternative investment opportunities and other market conditions.

15:04 EST Haemonetics lower after FDA clears Terumo plasma collection system - Shares of Haemonetics are down $3.64, or 6%, to $55.76 after the U.S. Food and Drug Administration announced this afternoon that it had cleared the new plasma collection system developed by Terumo Blood and Cell Technologies, or Terumo BCT. "Rika is a next-generation automated technology focused on the experience of plasma center employees and donors. It includes safety features to minimize operator errors and collects plasma in 35 minutes or less. Rika will debut this spring in a limited market release at CSL Plasma collection centers in the Denver, Colorado area. Plans are underway for rollout at additional CSL Plasma centers in 2022," the FDA announced. Previously, in April 2021, Haemonetics had announced that CSL Plasma had informed the company of its intent not to renew its supply agreement with Haemonetics for the use of PCS2 Plasma Collection System devices as CSL and Terumo had announced a collaboration to gain U.S. regulatory clearance for a new plasma collector.

14:37 EST eBay announces launch of company's 'first digital wallet' and eBay Vault - In conjunction with its investor day event, eBay said: "eBay's tech-led reimagination continues to underpin future growth plans. Since eBay completed the migration to its new payments platform, the company has been improving the user experience and creating value for customers. Now, eBay is launching its first digital wallet where customers can use proceeds from their sales to conveniently purchase their next item or pay their selling expenses." In addition, the company stated: "The market for trading cards and collectibles continues to accelerate, and eBay is the biggest trading platform for these investment categories. Today eBay announced the eBay Vault - a 31 thousand square foot, secure storage facility and digital marketplace for trading cards and collectibles, with plans to expand into luxury goods. The eBay Vault will launch in the U.S. next quarter, and will provide peace of mind and convenience for the company's millions of buyers and sellers. Once an item is in the eBay Vault, customers know their valuables are secure and "instant sale" becomes the new reality. Ownership can transfer from seller to buyer in a matter of seconds - without the need to re-authenticate, re-package or ship the item anywhere. Keeping high-value inventory within the eBay ecosystem is significant for both buyers and sellers - and the Vault will make other planned features, like fractionalization and live commerce, possible for a wider audience. eBay is the only marketplace that can deliver this full suite of capabilities at scale, and signals the future of collecting. Within a few years, eBay expects the Vault will hold up to $3 billion in assets, making it one of the largest stores of non-governmental assets in the world."

14:19 EST eBay anticipates EPS to grow 10% year-over-year in 2023 - eBay expects volume leverage and operational efficiency to lead to margin expansion beyond 2022. Expects margins to expand by a total of 100 basis points across the following two years. This outlook implies operating income will grow at CAGR between 8%-9% from 2022 to 2024. Plans to return 125% of free cash flow to shareholders over the next 3 years through repurchases and dividends. Anticipates EPS to grow 10% year-over-year in 2023. Expects EPS to accelerate to mid-teens growth in 2024. Comments taken from eBay Investor Day.

14:15 EST Peloton to test monthly subscription model for equipment, content - "Get the full Peloton experience-the award-winning Peloton Bike and the cost of an All-Access Membership-for one low monthly fee. Join One Peloton Club, and get your entire household access to the Peloton Bike and our complete library of live and on-demand classes. Enjoy a variety of workouts-from cycling and strength to yoga and boxing-for one low monthly payment and zero commitment. You can cancel anytime. We'll even pick up your Join One Peloton Club, and get your entire household access to the Peloton Bike and our complete library of live and on-demand classes. Enjoy a variety of workouts-from cycling and strength to yoga and boxing-for one low monthly payment and zero commitment. You can cancel anytime. We'll even pick up your Bike for free," said the company in a statement. "In certain markets, at the time of joining the Program, you will be charged a one-time non-refundable delivery fee of $250. A credit card is required to join the Program. A monthly Program fee will be charged to your credit card beginning upon delivery of the Bike and each month thereafter, and includes the cost of the Peloton All-Access Membership. All Program fees are set out in your One Peloton Club Agreement," added the company in the posting. Reference Link

14:08 EST Gap says suspended deliveries to Russia - In a message sent to all Gap Inc. employees that was posted to the company's website, the company stated: "Our hearts are with all those directly and indirectly impacted by the tragic events in Ukraine. With a reported 2 million people fleeing the violence and suffering in the region-most of whom are women and children with little more than the clothes on their backs-Gap Inc.'s brands will make a collective in-kind donation of more than $1 million worth of women and children's clothes to the UNHCR for communities in need. We are also encouraging employees to contribute company-matched donations to USA for UNHCR, CARE and the International Rescue Committee. As a values-led company, one that is proud to do the right thing over the past 53 years in business, at this time, we have also suspended deliveries to Russia, where we have a small franchise presence. We also have a handful of franchise locations in the Ukraine, which are currently closed, and we are working through our partner to account for the safety of those employees." Reference Link

13:36 EST Carnival launches VeriFLY app fleetwide in U.S. homeports - Carnival Cruise Line announced that after a successful pilot of VeriFLY by Daon, which it identifies as "a secure and free digital health app allowing vaccinated guests to easily submit pre-embarkation information," Carnival has launched the app fleetwide for all ships in all of its U.S. homeports, stating that this makes Carnival "the largest cruise line to utilize VeriFLY." "VeriFLY helps our guests easily and securely complete pre-embarkation tasks right from their smartphone. Guests can save time at the port and get on board faster by completing the process via VeriFLY," said Carnival Cruise Line President Christine Duffy.

13:01 EST Sirius XM signs exclusive multiyear agreement with reVolver Podcasts - SiriusXM announced an exclusive distribution and sales agreement with reVolver Podcasts, a multicultural, audio-on-demand content creator and publisher in the U.S. The new deal gives SXM Media, the combined advertising revenue organization of Sirius XM Holdings Inc., exclusive global ad sales rights to reVolver's extensive lineup of podcasts, the company said in a statement, adding that the agreement calls for Stitcher, a SiriusXM subsidiary, to distribute all reVolver content across all podcast platforms. "reVolver Podcasts is honored to be entering into this exclusive agreement with such a respected leader in the audio space," said Jack Hobbs, CEO of reVolver Podcasts. "We are confident that this relationship with SiriusXM will help solidify reVolver's place as the leader in multicultural podcasts, while providing new audiences and advertising opportunities for our network of incredible creators."

12:37 EST Meta adds new anti-misinformation features to Facebook Groups - Meta announced new features to help Facebook group admins keep their groups safe and healthy, reduce misinformation, and to make it easier for them to manage and grow their groups with relevant audiences. These new tools will help admins prevent the spread of misinformation and manage interactions in their group: Adding the ability through Admin Assist to automatically decline incoming posts that have been identified as containing false information. Incoming posts that contain content rated by third-party fact-checkers as false are declined before they are seen in the group, which helps reduce the visibility of misinformation; Expanding the functionality of "mute" and updating it to "suspend," so admins and moderators can temporarily suspend group members and participants from posting, commenting, reacting, participating in a group chat, and creating or entering a Room in a group. Reference Link

12:06 EST B.O.S. Better Online acquires Dagesh assets for NIS 2.3M - B.O.S. Better Online Solutions announced that its RFID division acquired the assets of Dagesh, which provides inventory counting services in Israel, mainly for retail stores. In consideration for the acquisition, BOS shall pay NIS 2.3M of which NIS 1.5M was paid at the closing, NIS 700,000 shall be paid by April 2022, and NIS 100,000 shall be paid by March 2023. In addition, BOS shall pay to Dagesh, by March 2023: An earn-out payment of 3%-6% of the revenues of the acquired assets in the 12 months ending February 28, 2023, provided that these revenues are in excess of NIS 2.5M; and NIS 100,000, upon the retention of at least 50% of the employees of Dagesh by BOS.

12:00 EST Coupang falls -20.5% - Coupang is down -20.5%, or -$4.66 to $18.05.

12:00 EST Asana falls -24.8% - Asana is down -24.8%, or -$12.10 to $36.71.

12:00 EST Genesco rises 11.4% - Genesco is up 11.4%, or $7.22 to $70.28.

11:59 EST China Green trading resumes

11:53 EST eBay jumps 3% as company presents at 2022 Investor Day event

11:39 EST BMW, Qualcomm, Arriver announce automated driving cooperation pact - BMW Group, Qualcomm Technologies, and Arriver Software AB announced a long-term development cooperation for the development of Automated Driving technologies. The companies signed an agreement for a strategic cooperation, which will focus on joint development of next-generation AD technologies ranging from New Car Assessment Program, Level 2 Advanced Driving Assistance Systems to Level 3 High Automated Driving functionalities. The co-development of software functions is based on the current BMW Automated Driving software stack first launched with the BMW iX in 2021, which will be further extended in the next generation through this cooperation. Reference Link

11:15 EST MorphoSys discontinues U.S. discovery activities, takes EUR 231M charge - MorphoSys announces that it will account for a non-cash impairment charge on goodwill in the amount of EUR 231M. The write-down results from the consolidation of the company's research and discovery activities after the acquisition of Constellation Pharmaceuticals. "MorphoSys decided to focus its research activities on the most advanced programs and to centralize all laboratory activities at its German research hub in Planegg, Germany. Consequently, all US-based activities relating to discovery biology and drug discovery departments were discontinued," the company said in a statement. "Therefore, early pipeline projects cannot be realized anymore and the expected cash flows from these projects will not materialize accordingly," MorphoSys added. The write-down has no cash effect and will impact operating expenses for Q4.

10:38 EST LoanDepot announces new operating unit called mello - loanDepot Founder and LDI Chairman and CEO Anthony Hsieh unveiled a new company operating unit: mello. mello will be led by newly appointed President and COO, Zeenat Sidi. LDI's new mello operating unit will complement the company's existing loanDepot mortgage and servicing operations platform, the company said in a statement.

10:29 EST Schneider appoints Shaleen Devgun as chief innovation, technology officer - Schneider announced it has appointed Shaleen Devgun to Chief Innovation and Technology Officer. Devgun's new role expands his current responsibilities as chief information officer to drive a series of innovation opportunities at the nexus of business strategy and technology to position the organization to thrive well into the future.

10:01 EST Polk County, Florida selects OpenCounter for permitting - OpenCounter announced that Polk County, FL has selected the company's permit discovery solutions to streamline the permitting and land development processes for residents, business owners, and the development community.

10:00 EST KE Holdings falls -19.6% - KE Holdings is down -19.6%, or -$2.83 to $11.63.

10:00 EST Amplify Energy rises 10.0% - Amplify Energy is up 10.0%, or 54c to $5.93.

10:00 EST LSB Industries rises 13.1% - LSB Industries is up 13.1%, or $2.44 to $21.02.

09:47 EST KE Holdings falls -19.9% - KE Holdings is down -19.9%, or -$2.88 to $11.58.

09:47 EST Build-A-Bear falls -23.4% - Build-A-Bear is down -23.4%, or -$4.59 to $15.04.

09:47 EST Amplify Energy rises 8.3% - Amplify Energy is up 8.3%, or 45c to $5.84.

09:45 EST Trean Insurance Group trading resumes

09:31 EST Ferguson says special resolution to transfer listing category passes vote - The Company is pleased to announce that, at its General Meeting held earlier today, the special resolution was passed by 95.49% of the votes cast, and the full results of the poll are set out in the table below. Following the vote, Ferguson will transfer its listing category from a premium listing to a standard listing on the London Stock Exchange and its primary listing will be the New York Stock Exchange. Today's announcement follows strong support from shareholders voting to implement the additional US listing in July 2020, and the commencement of trading of Ferguson's ordinary shares on the NYSE on March 8, 2021.

09:30 EST Western Union suspends operations in Russia, Belarus - Western Union issued the following statement: "All of us share the shock, disbelief, and sadness around this tragedy and humanitarian disaster. Our hearts go out to the people of Ukraine and to our colleagues, customers, agents, and partners who have been impacted. For the past weeks, our teams have been working to support our Ukrainian customers, including the millions who have been forcibly displaced, in the best ways we can. This includes donations to support humanitarian relief efforts and fee-free money transfer services. We also have engaged in extensive dialogue with a wide variety of stakeholders in an earnest effort to arrive at the right decision regarding our services in Russia and Belarus. We have thoroughly evaluated internal and external considerations, including the consequences for our valued teammates, partners, and customers. Ultimately, in light of the ongoing tragic impact of Russia's prolonged assault on Ukraine, we have arrived at the decision to suspend our operations in Russia and Belarus. We join the international community in expressing sincere hope for a diplomatic and peaceful resolution. Meanwhile, our priorities remain the well-being and safety of our employees as well as continuing to support the people of Ukraine, including the growing number of refugees seeking safety."

09:28 EST Wuhan General says M2Bio Labs offers Ketamine, Supercharged Vitamin IV therapy - WUHAN GENERAL GROUP is pleased to share the following update: M2Bio Sciences is pleased to announce the rollout of its on-site Ketamine and Supercharged Vitamin IV Therapy at the M2Bio Labs in Hout Bay, Cape Town. Drip therapy has long been used in hospitals and clinics to administer medicine for the main benefit of 100% bioavailability. This means that all the medicine, nutrients, or minerals are absorbed by the body because it's being fed directly into the bloodstream. The customized intravenous vitamin drips will offer various therapies and vitamin cocktails designed to target very specific health needs. They will support your physical and mental well-being, detox the body, boost the immune system, assist with recovery from strenuous training sessions, nourish and repair hair, skin, and nails, all to get your mind and body to peak performance. Patients will be treated in sessions typically lasting 2-3 hours, this process includes the ketamine administration by fully qualified members of the medical team in a comfortable environment. The medical staff will consist of doctors, nurses, psychologists, and psychiatrists. Patients will be fully guided through the entire process.

09:24 EST Troika Media signs firm commitment for $75M senior secured credit facility - Troika Media Group announced that it has signed a $75 million firm commitment for a senior secured credit facility with a direct lender, having extensive experience providing bespoke credit solutions to fund the Company's previously-announced definitive purchase agreement to acquire Converge Direct LLC and its affiliates, a leading digital and offline performance media and marketing company. The Company will fund the acquisition using net proceeds from the credit facility, together with cash on hand at closing to fund the cash consideration of the acquisition and will issue $25 million in the Company's restricted common stock valued at $2.00 per share. The restricted stock being paid to the Converge shareholders is restricted and subject to a nine-month lock-up agreement. Upon closing, Converge's management team will enter into long-term Employment Agreements and take an active leadership role in the combined business. Sid Toama, Chief Operating Officer of Converge, will join Troika's Board of Directors, and serve as President of Troika. Tom Marianacci, Founder and Chief Executive Officer of Converge will remain CEO of the Converge entities and be a board advisor to Troika. Other members of Converge's Executive Leadership Team have also agreed to enter into long term employment agreements to join Troika. The transaction is expected to close on or before March 15th, 2022. Converge has recorded unaudited revenues of approximately $300 million, $23 million of adjusted EBITDA and approximately $21 million of net income for the year ended December 31st, 2021, and Troika is anticipating having a combined adjusted EBITDA of over $27 million for calendar year 2022.

09:23 EST Matterport announces current results of ID Plans' partnership - Matterport announced that ID Plans, a commercial real estate, CRE, marketing and technology solutions provider, has helped property managers achieve up to 65% in cost and time savings by adopting Matterport digital twins. "ID Plans has partnered with Matterport to improve multiple aspects of its business," the company said. ID Plans uses digital twins to create accurate, user-friendly marketing ready packages to improve speed to lease, while their facilities management and operations teams utilize Matterport for remote site inspections and collaboration across their construction and design teams. "Within the property sales and leasing segment, the biggest drivers of demand for digital twins have been in retail and office leasing where brokers use digital twins to qualify and lease properties faster while tenants look for creative ways to visualize potential spaces," said Archana Kshirsagar, Head of Business Strategy, Commercial Real Estate at Matterport. "In the property design and facilities management segment, Matterport's CRE customers use remote collaboration to reduce unnecessary business travel as companies look for ways to optimize project development services and equipment repair and installations.

09:20 EST Saga Communications sees 2022 capex $5.5M-$6M

09:19 EST CEA Industries' Surna Cultivation signs $2.1M contract - CEA Industries subsidiary, Surna Cultivation Technologies announced it earned another multi-million-dollar contract. "We are pleased to announce a signed contract for $2.1 million with a facility in Maryland," said Jon Kozlowski, Surna's Vice President of Sales. "Earlier in 2021, Surna performed the mechanical, electrical, and plumbing (MEP) engineering services for this 37,000 square feet of cultivation space. Thanks to the value added as a result of this work, we have been awarded the HVACD and controls equipment portion of the project." This project includes HVACD equipment for the veg, flower, mother, clone, and dry cure rooms, as well as comfort cooling in the office spaces. As part of the HVACD equipment order, Surna is providing its EnviroPro air handlers, IsoStream fan coils, Surna by Anden dehumidifiers and humidifiers, boilers, and chillers. The project also includes controls design services and Surna's proprietary controls system, SentryIQ. The SentryIQ system will control the mechanical system, lighting, CO2 injection, and exhaust/purge systems and intake.

09:18 EST Ceapro signs long-term supply, distribution agreement with Symrise - Ceapro announced the signing of a long-term agreement with German-based multinational, Symrise AG, for the distribution and commercialization of Ceapro's high value active ingredients to major key international players in the cosmetic market. Under the agreement, Symrise is guaranteed to purchase minimum annual volumes of Ceapro's high value active ingredients. Financial terms of the agreement were not disclosed.

09:17 EST DraftKings to deliver sports betting coverage of tournament brackets - Debuting this Sunday, DraftKings will leverage the power of its growing media portfolio to deliver extensive sports betting coverage of the tournament brackets. Accessible via DraftKings' YouTube Channel and Vegas Sports Information Network, sports fans will receive comprehensive analysis of the opening betting lines for this year's Men's College Basketball Tournament, real-time analysis, breaking news and wall-to-wall coverage from the industry's most knowledgeable sports betting experts and sports personalities.

09:16 EST General Electric says Renewables financial results 'unacceptable, but fixable' - Expects losses for Renewables unit through 2023. Says Renewables margins, cash to be negative, but improve through 2023.

09:15 EST Seanergy Marine declares regular quarterly dividend of 2.5c per share - Initiates a regular quarterly dividend and declares dividend of $0.025 per share for the fourth quarter of 2021

09:12 EST Progenity progresses its DDS clinical device performance studies - Progenity announced progress with its clinical device performance study plan, evaluating the device function and safety of its Drug Delivery System, DDS, capsule. Progenity's first clinical device performance study evaluated the safety and tolerability of its DDS capsule and validation of the device's localization and delivery function in healthy volunteers. The DDS capsule was well tolerated and the study demonstrated the ability to accurately identify entry into the colon in 10 out of 12 subjects, trigger release of a liquid payload, and achieve pan-colon distribution with no devices deploying before entering the colon. "Having completed a successful study in healthy volunteers, we are now recruiting patients with active ulcerative colitis to continue evaluating the performance of our clinical device," said Adi Mohanty, Chief Executive Officer of Progenity. "These studies are important steps toward our goal of initiating a therapeutic intervention trial for our PGN-600 program to evaluate delivery of therapeutics directly to the site of disease in patients suffering from ulcerative colitis, and if we are able to establish accurate delivery in ulcerative colitis, the platform should also be applicable for localized delivery of other drugs."

09:11 EST Sintx Technologies awarded Phase 1 grant $300,000 from NIH - SINTX Technologies announced a Phase 1 grant of $300k awarded by the National Institutes of Health, NIH, to develop, design and characterize 3D printed implants for craniomaxillofacial, CMF, applications using a composite of silicon nitride and polyetherketoneketone, SN-PEKK. The Phase I grant represents the second grant awarded to SINTX by the NIH in the past six months. SINTX will collaborate with Drexel University, Thomas Jefferson University, and the University of Pennsylvania over the next 9-11 months to develop and test a new composite material for implants that combines the flexibility and durability of PEKK with the antibacterial and bone-integrating properties of silicon nitride. If successful, the new material could be used in place of other implant materials with higher failure rates and greatly improve patient outcomes and reduce healthcare costs. "The continued need for medical imaging compatible 3D printed biomaterials for CMF osteoplasty that can be personalized, promote integration, and prevent infection is significant," said Dr. Ryan Bock, Vice President of Research & Development, SINTX Technologies. "We believe that this high-performance silicon nitride PEKK material is a promising biomaterial for CMF applications because of its antibacterial activity, osseointegration, radiographic imaging, and durability. We're eager to demonstrate proof of concept through this NIH Phase I grant." The U.S. government funded research grant aims to provide a strong rationale and preliminary data to support the further study and commercialization of 3D printable silicon nitride PEKK composite for CMF implants which could substantially reduce implant failures due to infection and poor bone integration.

09:09 EST Suburban Propane acquires 25% equity stake in Independence Hydrogen - Suburban Propane purchased a 25% equity stake in Independence Hydrogen, a veteran-owned and operated supplier of gaseous hydrogen solutions, for $30.0M. The Partnership is creating a new subsidiary, Suburban Renewable Energy, as part of its long-term strategic goal of building out a renewable energy platform. In addition to the investment in Independence Hydrogen, Suburban Renewables will also hold the Partnership's 39% equity stake in Oberon Fuels acquired in September 2020. Oberon is a developer and producer of renewable dimethyl ether which, when blended with propane, can significantly reduce emissions and carbon intensity. The Partnership is continuing to invest in Oberon's technology and is working toward the commercial sale of propane +rDME blended products.

09:09 EST ZIM Integrated declares $17.00 per share dividend - Yesterday, along with announcing its consolidated results for the three and twelve months ended December 31, 2021, ZIM Integrated Shipping Services declared a cash dividend of approximately $2.04B, or $17.00 per ordinary share, reflecting approximately 50% of 2021 net income on a cumulative basis, including the $2.50 per share interim dividend paid in December 2021 on account of Q3 2021 results, in accordance with the company's dividend policy. The dividend will be paid on April 4 to holders of record of the ordinary shares as of March 23. Eli Glickman, ZIM President & CEO, stated, "In our first year as the only global container liner listed on New York Stock Exchange, ZIM has achieved historically extraordinary results and executed on commitments made during our IPO process. ZIM's agility and proactive strategies enabled us to unlock significant shareholder value during a time of unique and unprecedented challenges. With another quarter of exceptional financial performance, we generated our highest ever full year of revenues, adjusted EBITDA, net profit and operating cash flows, while once again delivering industry-leading margins. We also ended the year with a net positive cash position and strong financial flexibility. Given our outstanding cash generation in 2021, we decisively allotted capital to support our customers as we strive to provide best-in-class service. Importantly, we made sizable investments in equipment to facilitate the movement of cargoes for customers, as well as meaningfully expanded our operating fleet capacity and launched 17 new lines since June 2020, resulting in ZIM's year-over-year carried volume tripling the global volume growth rate. We also returned substantial capital to shareholders, highlighted by a full year dividend of $19.50 per share, reflective of 50% of our 2021 net income. In total, including our special dividend paid in September 2021, we will return to shareholders approximately $2.6 billion or $21.50 per share since our IPO, which represents approximately 30% of our current market cap and, incredibly, approximately 50% higher than our IPO market cap."

09:08 EST Rockley Photonics, Medtronic to enter Bioptx development partnership - Rockley Photonics (RKLY) announced that it has agreed to enter a development partnership with Medtronic (MDT). The two companies plan to collaborate to bring Rockley's recently announced Bioptx biomarker sensing platform into Medtronic's solutions for use across various healthcare settings.

09:07 EST Castor Maritime announces new charter agreements - Castor Maritime announces that: The M/V Magic Moon, a 2005 built Panamax dry bulk carrier, has been fixed on a time charter contract at a gross daily charter rate of $25,000. The charter commenced on March 6, 2022, and has a minimum duration of about 30 days. The M/V Magic Argo, a 2009 built Kamsarmax dry bulk carrier, has been fixed on a time charter contract at a gross daily charter rate equal to 103% of the average of the Baltic Panamax Index 5TC routes1. The charter is expected to commence on April 4, 2022, and will have a minimum duration of twelve months and a maximum duration of fifteen months at the charterer's option. The M/V Magic Venus, a 2010 built Kamsarmax dry bulk carrier, has been fixed on a time charter contract at a gross daily charter rate equal to 100% of the average of the Baltic Panamax Index 5TC routes1. The charter is expected to commence on April 15, 2022, and will have a minimum duration of about thirteen months and a maximum duration of about fifteen months at the charterer's option.

09:06 EST AvePoint launches Entrust product for Microsoft 365 users - AvePoint launched Entrust, a new product designed to streamline the management of Microsoft 365 admin users, processes, and data insights. Across one or multiple Microsoft 365 tenants, businesses can now use Entrust to delegate administrative control, centralize and monitor IT activity, and maximize their investment in, and company adoption of, the Microsoft ecosystem.

09:04 EST Volkswagen selects Upstart Auto Retail as a preferred digital retail provider - Upstart (UPST), an artificial intelligence AI lending platform, announced its Upstart Auto Retail product was selected by Volkswagen (VWAGY) as one of its preferred digital retail providers to modernize dealerships through an omni-channel car buying experience. "Online shopping and purchase behaviors have redefined the consumer experience so much that it's now become an expectation across other industries, including auto," said Michia Rohrssen, GM of Upstart Auto Retail. "There's a huge appetite on both sides-consumers wanting to browse, shop, and build deals online at their own pace, and manufacturers and dealers eager to embrace and extend their digital retail solutions. Volkswagen has consistently been at the forefront of innovation, and we are excited to power their digital retail expansion and initiatives now and in the future."

09:03 EST Siemens launches $100M decarbonization capital program - Siemens Smart Infrastructure and Siemens Financial Services launched a $100M capital program aimed at advancing the decarbonization goals of small to medium sized enterprises. This infusion of capital will help small and medium businesses in the U.S. jumpstart their decarbonization efforts.

09:02 EST SentinelOne promotes Mark Parrinello to CSO, Eran Ashkenazi to CCO - SentinelOne announced two executive promotions to further expand its C-suite. Mark Parrinello has been promoted to chief sales officer, or CSO, and Eran Ashkenazi has been promoted to chief customer officer, or CCO, effective immediately.

09:01 EST Greenlane appoints Craig Snyder as CCO - In addition, the Company has appointed Craig Snyder as its new Chief Commercial Officer, effective March 28, 2022. Mr. Snyder is an experienced leader with over 20 years of success in driving growth and development of high tech and emerging technology organizations. Mr. Snyder's day-to-day responsibilities will be focused on managing the commercial side of Greenlane's business, from developing the Company's go-to-market strategies to bolstering its sales initiatives. He will also be focused on digitally transforming the Company's Consumer Goods strategy, and getting more Greenlane Brands products into the hands of consumers through more traditional channels, such as Amazon.

09:01 EST Greenlane CMO Adam Schoenfeld steps down - The Company has reached a mutual agreement with Adam Schoenfeld for Mr. Schoenfeld to step down as Chief Marketing Officer, effective March 31, 2022. Mr. Schoenfeld is a co-founder and board member of Greenlane. The Company will not seek to fill the vacant role of Chief Marketing Officer at this time. Mr. Schoenfeld will continue to serve on the Company's board of directors.

08:59 EST Greenlane completes reduction in force, expects $8M in annualized savings - As part of its ongoing cost-cutting initiatives to accelerate the path to profitability, Greenlane completed a reduction in force, which the Company expects will result in approximately $8.0 million in annualized cash compensation cost savings. The reduction in force encompassed a broad spectrum of divisions both domestically and abroad. In conjunction with the reduction in force, the Company is also implementing additional profit enhancing initiatives, such as reducing its facility footprints worldwide and adjusting its go-to-market strategy significantly to reduce its operating costs and enhance liquidity. The Company expects these initiatives to help it achieve adjusted selling, general & administrative expenses of between approximately $14.0 million and $16.0 million on a quarterly basis by Q3 2022, down from approximately $26.6 million in Q3 2021. Additional strategic measures that the Company is pursuing or intends to pursue in order to capitalize the business in a non-dilutive manner, include: Conducting a sale leaseback of the Company's headquarter building; Disposing of non-core assets; Discontinuing sales of lower-margin 3rd-party brands and selling existing inventory; Raising prices on select products; and, Securing an asset based loan that will support working capital needs. The Company expects this plan to help generate liquidity in excess of $30 million if all measures described above are implemented successfully. Management believes this amount is sufficient to support the growth of the business in a non-dilutive manner by allowing the Company to reinvest capital into its highest margin and highest growth potential product lines, such as its Greenlane Brands.

08:57 EST Engine Gaming's Eden Games announces Gear.Club Stradale - At Apple Inc.'s Peek Performance event, hosted on March 8, 2022, Apple announced Eden Games', a subsidiary of Engine Gaming & Media Holdings, latest expansion of the Gear.Club franchise, Gear.Club Stradale, as the "next big release" coming exclusively to Apple Arcade.

08:54 EST Jerash Holdings to manufacture clothing for Timberland brand - Jerash Holdings announced the addition of a new branded customer, with the receipt of orders to manufacture clothing for Timberland, an outdoor lifestyle brand and part of VF Corporation.

08:52 EST U.S. Gold contracts Samuel Engineering for next phase of CK Gold Project - U.S. Gold has awarded Samuel Engineering the next phase of engineering for its CK Gold Project in southeast Wyoming. Several engineering firms submitted bids to conduct the next phase of engineering that can lead to a full feasibility study and necessary engineering to support project development. Samuel has been in business for 25-years and is headquartered in Denver, Colorado. Samuel has is an office in Rock Springs Wyoming and a presence in Douglas.

08:50 EST Vivakor secures long term oil sands supply, lease agreement - Vivakor announced the signing of a lease with Tar Sands Holdings II and an agreement with Greenfield Energy, which, together, are expected to provide Vivakor with multiple years of rich oil sands supply, along with access to world class operational services. The multi-year lease allows Vivakor up to 2,000 tons per day of oil sand material, which is guaranteed by TSHII to be at a minimum of 10% hydrocarbon by weight, that is expected to produce up to 200 tons of asphalt cement per day when processed through four of Vivakor's patented Remediation Processing Centers. Currently, the Company has one RPC, which is in the process of being scaled up to full capacity of 50 tons of asphalt cement per day, which is anticipated to be completed by the end of the second quarter this year. Vivakor's existing RPC machine in Utah has demonstrated the ability to produce asphalt cement that independent testing has determined meets roadway performance grade specifications. In light of increasing oil prices and asphalt cement scarcity, wholesale prices now exceed $450 per ton in this region, having increased by approximately 30% since December 2021. Resource estimate reports for this mine indicate more than 40 million barrels of recoverable heavy crude. The Company's arrangement with Greenfield includes a Professional Services Agreement between Greenfield and Vivakor, which provides for Valkor, LLC, an energy services company with extensive operations, fabrication and installation experience, to perform certain operating and engineering services to increase the production capabilities of the Vivakor plant to enable it to produce upwards of 1,000 barrels per day or 1,000 tons of asphalt cement per week once three more RPCs are financed and built. Vivakor and Greenfield will also be exploring the treatment and commercialization of the post processed, cleaned sand material that is residual after the extraction of the bituminous material in the creation of asphalt cement. Early indications show promising signs of the economic value of this sand for various applications.

08:49 EST Moderna doses first patient in Phase 2 study of mRNA-1273.214 - Moderna announced that the first participant has been dosed in the Phase 2 study of the Company's Omicron-specific bivalent booster candidate, which combines Moderna's Omicron-specific booster candidate and the Moderna COVID-19 vaccine. This extension of an earlier study will evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.214 as a single booster dose in adults aged 18 years and older who previously received the two-dose primary series of mRNA-1273 and a 50 microgram booster dose of mRNA-1273 with the booster dose being at least three months ago. Moderna expects to enroll approximately 375 participants, which will be conducted at approximately 20 sites in the U.S. Moderna is also evaluating its Omicron-specific booster candidate in a Phase 2 study in the U.S. Separately, the Company is evaluating mRNA-1273.529 in a Phase 3 study the UK in collaboration with the National Institute for Health Research. The Company expects to begin dosing with mRNA-1273.214 in that study soon.

08:40 EST Ageagle announces eBee TAC solution added to Blue UAS Cleared List - AgEagle Aerial Systems announced that senseFly, an AgEagle subsidiary, is one of the first eleven vendors to complete the required testing, evaluations and demonstration process to be designated a Blue UAS under the Defense Innovation Unit's Blue sUAS 2.0. As a result, the NDAA-compliant eBee TAC Unmanned Aerial Systems, pioneered by senseFly, has been approved by the Defense Innovation Unit for procurement by the U.S. Department of Defense. In an announcement released yesterday, the DIU stated, "The first approved drone to be added to the DIU Blue UAS Cleared List as part of Blue sUAS 2.0 is the eBee TAC by senseFly, an AgEagle company. Systems added to this list do not require a DoD exception to policy to procure or operate as they have undergone a cyber-security evaluation, a policy compliance check, and were issued the necessary administrative documentation. Federal government partners can also leverage this effort for their programmatic needs without duplicating efforts."

08:38 EST Triumph Bancorp appoints Bahr as Chief Revenue Officer of TBK Bank - Triumph Bancorp announced the appointment of Erik Bahr as chief revenue officer of TBK Bank, SSB, member FDIC. "In the newly created role, Bahr is responsible for driving go-to-market strategy, sales performance, client satisfaction, and overall operations of the sales channels and partnership for the bank's transportation lines of business. Additionally, Bahr will improve the enterprise offering to its transportation clients and manage all activities associated with transportation-related revenue generation," the company said. Bahr has more than 25 years of experience in technology sales and leadership. He joined Triumph Business Capital, a subsidiary of TBK Bank, in early 2020 as executive vice president, where he led revenue production, partnerships and enterprise sales.

08:37 EST eMagin implements product price increases for 2022 - In response to ongoing supply-chain, capacity and pricing pressures, the Company continues to monitor its wafer suppliers and is creating backplane designs suitable for alternative foundries to be able to optimize its allocations. In addition, the Company has implemented product price increases for 2022.

08:34 EST Allogene Therapeutics receives FDA Fast Track designation for ALLO-316 - Allogene Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation, FTD, to ALLO-316, the Company's first AlloCAR T solid tumor clinical candidate for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma, RCC. The FDA granted FTD based on the potential of ALLO-316 to address the unmet need for patients with difficult to treat renal cell carcinomas who have failed standard RCC therapies. "Metastatic solid tumors have historically been a challenge to treat regardless of treatment modality, creating a large unmet need for patients and a necessity for scientific innovation," said Rafael Amado, M.D., Executive Vice President of Research and Development and Chief Medical Officer. "We have our sights set on confronting solid tumors where the need is unquestionably high. We remain optimistic for the potential of our AlloCAR T platform to address the challenge and we look forward to generating data from our ongoing Phase 1 trial."

08:32 EST AFC Gamma raises quarterly dividend 10% to 55c per share - AFC Gamma's Board of Directors has declared a cash dividend of $0.55 per share of common stock, payable on April 15, 2022 to the stockholders of record as of March 31, 2022, representing an increase of 10% over the prior quarter's dividend

08:29 EST Small Pharma provides R&D updates on SPL028, SPL026 - Small Pharma announces research and development updates on two N,N-dimethyltryptamine based candidates, SPL028 and SPL026. Small Pharma's pipeline of short duration psychedelics have the potential to offer effective, accessible and practical in-clinic treatments with patients and clinicians in mind for a range of mental health conditions. Two additional trials have been added to SPL026's development program while the SPL028 program moves towards a Phase I clinical trial in H2 2022. Following the success of its lead DMT candidate SPL026's Phase I trial, Small Pharma is expanding its development program with the addition of a drug interaction study, planned for 2022. This study will assess the impact of antidepressants on the safety, tolerability, pharmacokinetics and pharmacodynamics of SPL026 with psychotherapy. These endpoints will be assessed in patients with Major Depressive Disorder, who are currently on a course of selective serotonin reuptake inhibitors but have not achieved satisfactory results, compared with those not taking an SSRI. A better understanding of how DMT-assisted therapy interacts with existing antidepressants opens up the potential to reach the broadest population of patients suffering from MDD. Small Pharma is also planning a further Phase I study of SPL026 with healthy volunteers in 2022 to compare the treatment profile of intramuscular versus intravenous modes of administration. IM injection would offer a simple injectable form that could further enhance convenience and accessibility for patients and clinicians. Small Pharma has advanced its proprietary deuterated DMT candidate SPL028 through preclinical studies. The goal is to deliver a treatment with an extended psychedelic experience, as compared to SPL026, but still significantly shorter than the experience of other psychedelics, such as psilocybin and LSD. Through SPL028, Small Pharma is exploring whether an extended duration could offer a DMT treatment tailored for other mental health conditions. Additionally, the pharmacokinetic profile of SPL028 offers the opportunity for optimizing alternative routes of administration beyond IV. The final candidate of SPL028 was selected after screening a range of deuterated DMT compounds through in vitro and in vivo studies. Importantly, preclinical studies suggest that SPL028 offers a similar safety and pharmacological profile to SPL026, while being differentiated by its pharmacokinetics, to offer a potentially extended psychedelic experience as compared to SPL026. Key parameters include: Safety profile: SPL028 has the potential for a similar safety profile to SPL026 in the clinic. In vitro and ex vivo binding: data suggest a similar binding affinity across a range of receptors including 5-HT receptor subtypes, which are believed to induce psychoactive effects. Toxicology: SPL028 found to be safe and well-tolerated in vivo at all doses tested, demonstrating significant safety margins for progressing into first-in-human trials. Behavioral effects: Similar but prolonged behaviors induced by SPL028 in a number of preclinical models were observed in vivo, suggesting the potential for a similar but longer psychedelic experience as compared to SPL026. Pharmacokinetic profile: In vitro data of SPL028 demonstrated a reduction in clearance rate and significant extension in half-life compared to SPL026. Following IM administration in vivo, SPL028 demonstrated a marked decrease in clearance from the body, resulting in higher blood concentrations for an extended period of time versus SPL026. In H2 2022 Small Pharma intends to initiate a Phase I study of SPL028 with psychotherapy among healthy volunteers to assess safety, tolerability, pharmacodynamics and pharmacokinetics of IM and IV administration. This study will allow Small Pharma to better understand the profile of SPL028 as a therapeutic candidate and identify the optimal route of administration in a clinical setting.

08:27 EST Vital Farms releases inaugural Sustainability Report - Vital Farms published its inaugural Sustainability Report, a comprehensive overview of the company's Environmental, Social, and Governance, ESG, progress with respect to each of its stakeholders, including farmers and suppliers, crew members, customers and consumers, communities and the environment, and stockholders. "While ESG is a relatively new journey for us, we have a long history of prioritizing areas like environmental conservation, human capital, community, and much more through our business model, which is rooted in stakeholder capitalism," said Joanne Bal, Vital Farms' General Counsel, Corporate Secretary, and Head of Environmental, Social, and Governance. "Our inaugural Sustainability Report is a detailed and data-driven look at the impact we've had on each of our stakeholder groups, demonstrating how we've grown our business while progressing our purpose to improve the lives of people, animals, and the planet through food. We look forward to the next phase of this work by publishing concrete, measurable goals for our top ESG issues, developing operational plans to meet these targets, and publicly reporting our progress."

08:25 EST Trean Insurance appoints Smith to board of directors - Trean Insurance announced that its Board of Directors has appointed a new independent director, Philip Smith, to its Board of Directors, effective immediately. Smith brings to the Board over 25 years of experience in finance and executive management. He is currently a managing director of Duff & Phelps, an investment banking firm that provides valuation, corporate finance and other services.

08:23 EST Global Crossing Airlines announces graduation to NEO Exchange - Global Crossing Airlines Group is pleased to announce that the Neo Exchange has granted final approval of the Company's listing application and that the shares of Common Stock and Class B Non-Voting Common Stock of GlobalX will commence trading on the NEO Exchange as of 9:30am ET on March 16, 2022. GlobalX's existing trading symbols "JET" and "JET.B" will remain unchanged as a result of the listing. The Company's shares will be delisted from the TSX Venture Exchange at the close of market on March 15, 2022.

08:22 EST Katapult appoints Gorsky as CMO, Diaz as CHRO - Katapult announced it has hired Colleen Gorsky as Chief Marketing Officer, CMO, where she will lead the scaling of Katapult's brand, partnership and marketing efforts. In addition, Katapult has hired Jorge Diaz as Chief Human Resource Officer, CHRO. Gorsky brings to Katapult more than 20 years of B2B2C marketing and partnerships experience in growth phase companies. Most recently, she served as VP, Partner Marketing at Klarna. As Katapult's CHRO, Jorge brings over 25 years of creating and executing successful talent strategies to the lease-to-own leader. Prior to joining Katapult, Diaz served as Chief People Officer for Coyote Logistics.

08:20 EST AbbVie's atogepant in chronic migraine meets Phase 3 primary endpoint - AbbVie announced that the Phase 3 PROGRESS trial evaluating atogepant - Qulipta in the U.S. -, an oral calcitonin gene-related peptide receptor antagonist for the preventive treatment of chronic migraine in adults, met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo, for both doses, across the 12-week treatment period. The study also demonstrated that treatment with atogepant resulted in statistically significant improvements in all secondary endpoints after adjustment for multiple comparisons. A total of 778 patients were randomized. Patients in the atogepant 60 mg QD and 30 mg BID treatment arms of the study, experienced a decrease of 6.88 and 7.46 monthly migraine days, respectively, compared to patients in the placebo arm. The overall safety profile of the Phase 3 PROGRESS study was consistent with safety findings observed in previous studies in an episodic migraine population. The most common adverse events reported were constipation and nausea. Most of the events of constipation and nausea were mild or moderate in severity. Based on the results of phase 3 PROGRESS trial in chronic migraine, AbbVie intends to submit a supplemental New Drug Application with the FDA for the expanded use of atogepant to include the preventive treatment of chronic migraine. Additionally, study results will form the basis for future regulatory submissions globally.

08:20 EST Iterum Therapeutics granted 180-day extension by Nasdaq to regain compliance - Iterum Therapeutics announced that the Company received written notification from the Listing Qualifications Department of The Nasdaq Stock Market, granting the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company now has until September 5, 2022 to meet the requirement. If at any time prior to September 5, 2022, the bid price of the Company's ordinary shares closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will regain compliance with the Bid Price Rule, and the matter will be closed. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq staff determined that the Company was eligible for an additional 180 calendar day period, or until September 5, 2022, to regain compliance based on the Company meeting the continued listing requirement for the market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company having provided written notice of its intention to cure the deficiency during the second compliance period, including by effecting a reverse share split, if necessary. If the Company does not regain compliance with the Bid Price Rule during the additional 180-day extension, Nasdaq will provide written notification to the Company that its ordinary shares will be delisted. At that time, the Company may appeal the relevant delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance that, if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful.

08:19 EST KULR Technology appoints William Walker as director of engineering - KULR Technology Group has appointed Dr. William Walker as its new Director of Engineering. In his new role, Dr. Walker will work with the Company's engineering team on its next generation high-performance computing and hypersonic vehicle thermal management initiatives. Prior to KULR, Dr. Walker was employed by NASA Johnson Space Center where his career primarily focused on the design and optimization of safe lithium-ion battery assemblies for human spaceflight applications.

08:17 EST General Electric sees Healthcare unit long term revenue growth mid single digits - Sees Healthcare unit long term profit margin high teens to 20%; FCF conversion 100%+. For FY22, sees Healthcare revenue growth low single to mid single digits; profit margin improvement 25-75 bps; FCF conversion greater than 100%. Says Healthcare unit to be investment grade on day one after spinoff. Confirms early 2023 for Healthcare unit spinoff.

08:16 EST Kratos' OpenSpace Platform supports Carrier Ethernet-over-Satellite - Kratos Defense & Security Solutions announced that its OpenSpace Platform now supports integrated delivery of E-Line services using Carrier Ethernet-over-Satellite. Kratos' OpenSpace Platform is the first and only completely virtual satellite ground system based upon an open, standards-based Software-Defined Networking architecture that enables satellite operators and global communications networks to interoperate seamlessly. Introduced last year with support for Earth Observation and Remote Sensing missions, the OpenSpace Platform now adds support for E-Line Carrier Ethernet Services through its SCPC Service Chain, enabling operators to expand their offerings to include use cases where a two-way satellite segment is beneficial, such as service delivery to remote locations underserved by terrestrial or cellular technologies.

08:15 EST Lightbridge to postpone issuing FY21 results - Lightbridge Corporation announced that it will postpone issuing its results for Fiscal Year 2021. Lightbridge is in the process of finalizing its 2021 financials. Once completed, a press release announcing Fiscal Year 2021 results will be issued. Lightbridge will hold its previously scheduled Business Update Conference call later today at 11am ET to discuss the Company's corporate progress and other meaningful developments. However, we will not have commentary on the Company's financial results for the year ended December 31, 2021 on this call.

08:15 EST Augmedix announces new board member, Laurie McGraw - Augmedix (AUGX) announced that Laurie McGraw, a former Allscripts (MDRX) Executive, has joined its board of directors, effective March 9, 2022. McGraw is currently Senior Vice President, Health Solutions, a division of the American Medical Associations.

08:14 EST MedTech Acquisition, Memic mutually agree to terminate business combination - MedTech Acquisition Corporation and Memic Innovative Surgery announced that both companies have mutually agreed to terminate, effective immediately, their previously announced business combination agreement dated August 12, 2021 due to market conditions and associated volatility as a result of recent world events.

08:11 EST Enphase Energy expands battery storage in Wisconsin - Enphase Energy announced that Enphase installers in Wisconsin have seen growing deployments of the Enphase Energy System powered by IQ Microinverters and IQ Batteries. Residential storage capacity is poised for substantial growth in Wisconsin, with deployments expected to grow 15-fold by 2026, according to the most recent U.S. Energy Storage Monitor report from the Energy Storage Association and Wood Mackenzie.

08:09 EST Tracon Pharmaceuticals announces FDA approval of amended ENVASARC protocol - TRACON Pharmaceuticals announced that the first patient has been dosed following the approval of the amended ENVASARC protocol by the U.S. Food and Drug Administration. In December 2021, based on the highly tolerable safety profile and the significantly higher objective response rate observed in lower weight patients in ENVASARC, the IDMC recommended increasing the dose of envafolimab to 600 mg every three weeks, which is double the original envafolimab dose of 300 mg Q3W. Given the robust activity demonstrated by higher doses of envafolimab in previously completed studies, including in the pivotal trial in MSI-H/dMMR cancer that was the basis for approval of envafolimab in China, TRACON submitted the amended ENVASARC protocol in January that was cleared by the FDA in February. Patient dosing is now underway at this 600 mg Q3W dose.

08:07 EST aTyr Pharma to initiate registrational study of efzofitimod in Q3 - aTyr Pharma announced the positive outcome of a Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration regarding its lead therapeutic candidate, efzofitimod, for the treatment of pulmonary sarcoidosis. As a result, the Company intends to initiate a planned registrational study of efzofitimod in the third quarter of 2022. Following the FDA's review of the data package, including data from the nonclinical program, early clinical trials and the recently completed Phase 1b/2a study, the Company will proceed with the advancement of efzofitimod. The FDA discussed endpoints detailed by the Company in its proposed registrational study and prioritization of outcome measurements that would best support the evaluation of efzofitimod's efficacy. The FDA advised the continued evaluation of multiple doses of efzofitimod in a longer duration study to establish a controlled safety database that supports the determination of the optimal dose for chronic use.

08:05 EST InMode approves share repurchase program of up to 1M ordinary shares - InMode has approved a share repurchase program of up to 1 million ordinary shares on the open market or otherwise. The company's ordinary share repurchases, if any, will be funded with available cash. Share repurchases may be commenced, suspended or discontinued at any time.

08:03 EST Rush Street Interactive receives iGaming operator registration from AGCO - Rush Street Interactive announced that it has received its iGaming operator registration from the Alcohol and Gaming Commission of Ontario, or AGCO. RSI plans to satisfy all remaining regulatory requirements and launch its award-winning BetRivers online casino and sportsbook in Ontario on April 4, 2022, the first day online gaming will be authorized in the province.

08:03 EST SpartanNash promotes David Petko to Chief Supply Chain Officer - Food solutions company SpartanNash announced the promotion of David Petko to Executive Vice President and Chief Supply Chain Officer. Petko was hired in April as Senior Vice President and Chief Supply Chain Officer reporting to President and CEO Tony Sarsam. He oversees all aspects of SpartanNash's global supply chain, which serves 145 Company-owned stores, over 2,100 independent retailers and national accounts throughout the U.S., as well as U.S. military commissaries and exchanges around the world.

07:58 EST Deutsche Bank backs view of post-tax return on tangible equity of 8% for FY22 - Deutsche Bank said: "The current geopolitical and macroeconomic environment creates uncertainties whose impact cannot yet be fully assessed. Nevertheless, performance in January and February was ahead of the comparable period last year across key metrics as management continues to work toward delivery of its financial and transformation objectives for 2022. Group highlights for the year to date as of 28 February, including a two-month pro rata, or two-twelfths, share of Deutsche Bank's annual bank levy in both 2022 and 2021, include: Post-tax return on average shareholders' equity of 10.6%, versus 8.6% in the year to 28 February 2021; Post-tax RoTE of 11.8%, up from 9.7% in the year to 28 February 2021 and ahead of the 2022 target of 8%; Core Bank post-tax RoTE of 13.8%, up from 12.1% in the same period of 2021 and compared to a 2022 target of above 9%; Cost/income ratio of 64.1%, down from 68.0% in the same period of 2021 and below the full-year 2022 goal of 70%; CET 1 ratio of around 13.2%, well above the bank's 2022 goal of above 12.5%. Deutsche Bank aims to reach its 2022 goals through a combination of revenue growth, further reductions in adjusted costs ex-transformation charges1, and the substantial elimination of transformation-related effects, 97% of which were recognised by the end of 2021." CFO James von Moltke added: "For the full year 2022, we continue to expect to deliver a post-tax return on tangible equity of 8%. We have had a good start to the year across our businesses. While the war in Ukraine creates increased uncertainty in the market environment, our exposures to Russia are contained and well controlled."

07:54 EST Marathon Gold reports drill results from Valentine Gold Project - Marathon Gold reports the latest drill assay results from the Valentine Gold Project in central Newfoundland. These results represent 2021 drilling at the Victory and Sprite Deposits, and in the area of the proposed Marathon Waste Rock Facility, MWRF. The latest drill results represent fire assay data from 22 diamond drill holes completed at the Victory Deposit, 16 holes completed at the Sprite Deposit, and 21 holes completed at the MWRF. Matt Manson, President and CEO, commented: "The principal focus of our current exploration at Valentine is infill drilling at our Berry Deposit which has the potential to add a meaningful quantity of future gold resources to the Project's mine plan... We are particularly encouraged by the Victory area, where we are delineating an extensive system of alteration and gold mineralizing fluids over a broad area. This merits additional drilling in 2022. The mineralization at Sprite, as well as at the proposed site of the Marathon Waste Rock Facility, appears more localized, but is reflecting the ubiquity of gold mineralization almost everywhere along the length of the Valentine Lake Shear Zone which has been explored to date. Our 2022 exploration program is designed to bring out this larger potential, with prospecting along the full eastern arm of the property and drill programs at Berry and Victory."

07:51 EST General Electric says has suspended operations in Russia - Says Russia represents less than 2% of overall company sales. Says premature to factor potential war impacts on outlook. Says running businesses "with eye towards decentralization." Says seeing near-term improvements in businesses. In Healthcare: Order demand remains strong despite supply chain disruption; continuing to invest in growth while managing costs. In Power: Global gas demand remains steady; GE gas turbine utilization supporting stronger services & cash generation. In Renewable Energy: Increasing selectivity & managing cost at Onshore Wind; global demand continues at Offshore Wind. In Aviation: Confident in continued market recovery; positioned to lead as the commercial aftermarket recovers & military grows. Comments taken from Investor Day presentation.

07:51 EST Vitalhub enters licensing deal with North Middlesex University - VitalHub is pleased to announce a licensing agreement of subsidiary Intouch with Health's hardware and software solutions with North Middlesex University Hospital NHS Trust. The Trust is a new customer of the Company, with the transaction resulting from North Middlesex seeking a solution for ongoing operational pressures, and the need to tackle their growing Elective Care backlog. The Trust expressed keen interest in the Company's Patient Flow Management solutions, to enable effective use of their facility's rooms.

07:50 EST Shyft Group's Utilimaster debuts Velocity R2 walk-in van - Utilimaster announced it will reveal its new Velocity R2 walk-in van today at NTEA Work Truck Week. This new Velocity offering provides the comfort and agility of a cargo van with the cargo space and access of a walk-in van, improving the driver experience and optimizing delivery speed. Vehicle prototypes have already undergone the customer testing process, and production on a leading parcel delivery customer order of more than 2,500 units is expected to be completed later this year.

07:48 EST FTI Consulting partners with Reveal - FTI Consulting announced that the Technology segment has added Reveal, the global provider of the leading AI-powered e-discovery platform, to its bench of software partners. "The partnership will strengthen FTI Technology's early case assessment, AI and advanced analytics offerings, enabling fast access to insights supporting litigation, investigations, compliance, antitrust, data privacy matters and more," the company said. This partnership announcement extends an existing relationship between FTI Technology and Brainspace, a leading analytics platform that was acquired by Reveal in 2020. FTI Technology provides clients with a selection of analytics and e-discovery solutions across a range of software platforms for early case assessments, document review, processing, Story Development, data subject access requests and other use cases. "FTI Technology, now backed by a leading AI-powered platform for e-discovery, combines sophisticated solutions with experienced professionals to find innovative and defensible approaches to address today's challenging legal and regulatory matters," said Wendell Jisa, Founder and CEO of Reveal. "We are excited that this partnership will provide FTI Technology and its clients with more options to accelerate early case assessment, fact-finding and the discovery process."

07:47 EST Hillenbrand announces CFO transition - Hillenbrand is appointing Robert VanHimbergen, former VP and Corporate Controller at Johnson Controls, as Executive VP, Finance on March 14. VanHimbergen will assume the role of CFO on April 30. To ensure continuity and support an effective transition, Kristina Cerniglia, current SVP and CFO, will remain as CFO until April 29, at which time she will step down after eight years, to pursue other professional opportunities. VanHimbergen was most recently VP and Corporate Controller at Johnson Controls, a Fortune 100 company with 2021 annual revenue of nearly $25 billion. He spent 15 years at Johnson Controls. Prior to Johnson Controls, VanHimbergen spent nearly a decade at PwC working with large multi-national manufacturing companies.

07:45 EST Sensei Biotherapeutics expects cash to fund operations into at least 1H of 2024 - Cash, cash equivalents and marketable securities were $147.6 million as of December 31, 2021, as compared to $16.6 as of December 31, 2020. Sensei expects the current cash balance to fund operations at least into the first half of 2024.

07:43 EST Graybug Vision expects cash to fund operations into H2 of 2023 - As of December 31, 2021, the company's cash, cash equivalents, and short-term investments totaled $63.7 million, compared to $95.0 million as of December 31, 2020. The decrease was primarily due to its net loss in 2021 of $35.8 million. The company's current cash and investments are sufficient to support its planned operations into the second half of 2023.

07:40 EST Wingstop declares special dividend of $4.00 per share - Wingstop has authorized and declared a special dividend of $4.00 per share of common stock payable to stockholders of record as of March 24 to be paid on April 7.

07:38 EST Alithya Group signs multi-year Master Service Agreement with Canadian bank - Alithya Group signed a multi-year Master Services Agreement with a major Canadian financial institution. The Master Services Agreement with one of Canada's 'Big Six' banks consists of a 3-year term, with provisions for 2 one-year renewals. The Master Services Agreement ensures that Alithya can respond quickly to the needs of the business by reducing delays between definition and project initiation. The initial Statement of Work has been established at approximately C$4.7M, with two service agreements representing a cumulative value of C$2.9M already signed. Alithya's work for the bank will primarily revolve around project delivery services, particularly in the context of data and analytics. Alithya will assist the bank in consolidating and warehousing data as well as the business analysis to develop enhanced analytics for a variety of banking scenarios.

07:36 EST Oragenics, KBI Biopharma team for development of vaccine candidate NT-CoV2-1 - Oragenics announced it has entered into an agreement with KBI Biopharma for the process transfer, process optimization and cGMP manufacturing of the Company's intranasal vaccine candidate NT-CoV2-1, which is expressed in a proprietary CHO cell line. The agreement covers, among other things, both a 200L demonstration run and a 500L cGMP run. "We are delighted to enter into a development collaboration for our SARS-CoV-2 intranasal vaccine candidate with an outstanding commercial partner. Successful completion of work under this agreement will enable Oragenics to secure material for a future expected Phase 2 clinical trial. Intranasally delivered SARS-CoV-2 vaccines could provide increased protection in the nose and throat where viral entry occurs. This could lead to lower transmission of the virus compared to the currently available intramuscularly delivered vaccines as well as offering a needle-free delivery option," stated Frederick W. Telling, Ph.D., Executive Chairman of Oragenics...Oragenics previously demonstrated robust immune response and reduction of SARS-CoV-2 viral loads to undetectable levels in the nasal passages and lungs five days following a viral challenge in preclinical models. The company intends to file an IND in 2022 to conduct a first-in-human clinical study with NT-CoV2-1.

07:34 EST Dyne Therapeutics announces upcoming milestones - Upcoming Milestones: The Company expects to submit its response to the FDA for the DYNE-251 IND in DMD in the second quarter of 2022 with the goal of dosing patients in a Phase 1/2 global MAD clinical trial in mid-2022. Dyne now plans to submit regulatory filings in multiple countries for DYNE-101 in DM1 in the second quarter of 2022, and in accordance with its previous guidance, expects to initiate patient dosing in a global MAD clinical trial in mid-2022. Dyne expects to submit an IND for DYNE-301 in FSHD in the second half of 2022.

07:34 EST Chemours suspends business with Russian entities - The Chemours Company announced it has suspended business with Russian entities in response to the ongoing military conflict and humanitarian crisis. "Chemours condemns the senseless violence taking place and views continuing business as inconsistent with our company values. As always, we will work to meet the needs of our global customers throughout this process, however, we believe suspending business with Russian entities is the right thing to do," said Mark Newman, President and CEO for Chemours. "We will continue to monitor the situation closely and reassess in the future." Chemours also announced a $100,000 donation to the International Committee of the Red Cross to support humanitarian efforts in the region. "Every day we encourage our people to operate with the courage to make a difference. Over the past two weeks the people of the Ukraine have embodied such courage and perseverance. Now, we want to do our part and help make a difference by supporting those in need," said Newman. Chemours has a small office in Moscow and is working closely with employees to ensure their safety.

07:32 EST NFI Group lowers quarterly dividend to 5.31c per share - Although management continues to believe that the supply and logistics disruptions affecting NFI are temporary, the Board has taken the prudent decision to lower the quarterly dividend amount. The Board has declared a dividend of C$0.0531 per share for the period January 1, 2022 to March 31, 2022 on the common shares of the Company. The dividend will be paid to holders of record at the close of business on March 31, 2022 and payable on April 15, 2022. The dividends on the Shares are designated as "eligible dividends" for purposes of the enhanced dividend tax credit rules contained in the Income Tax Act and any corresponding provincial and territorial tax legislation. Given the expected temporary nature of the supply chain disruptions, NFI's management and Board believe that there will be an opportunity for dividend increases in 2023 if the Company's financial performance improves as expected. See Forward-Looking Statements.

07:29 EST Yellow Corp settles dispute with United States government - Yellow announces that it has reached an agreement with the United States government, settling a nearly 13-year-old civil litigation with the Department of Defense relating to credits for the reweigh of certain freight shipments between 2005 and 2013, all of which pre-date current management. In reaching that agreement, Yellow admitted no liability while denying the government's core allegations. The agreement will enable the company and its 30,000 freight professionals to remain centrally focused on transporting goods for more than 200,000 customers, including the Department of Defense. "We are pleased to have come to a resolution," said Darren Hawkins, CEO of Yellow. "Now we can continue to focus on the important work ahead. With our nation's current supply chain constraints and the critical role Yellow plays in delivering freight, there's no time for distraction. Putting this matter behind us also helps Yellow move forward with its corporate mission of transforming our nearly 100-year-old company into one of the nation's preeminent super-regional and long-haul less-than-truckload carriers."

07:24 EST Tiziana Life announces clinical data from SPMS patient treated with foralumab - Tiziana Life Sciences reported positive clinical data in a patient with Secondary Progressive Multiple Sclerosis, SPMS, following completion of six months of treatment with intranasally administered foralumab, at the Brigham and Women's Hospital, BWH, Harvard University, Boston, MA. In addition to being well-tolerated, both biological and clinical improvements were seen in this patient using Tiziana's novel immunotherapy technology, which, importantly overcame the challenge of delivering this antibody across the blood-brain barrier to affect immunomodulation in the brain. Prior to treatment, this patient had continued to experience worsening disease progression despite several MS therapies, including B cell depletion. The patient then started on intranasal foralumab, which stabilized his disease course. Tiziana also received FDA authorization to continue treating this patient for an additional 6 months to determine if 12 months of consistent treatment maintains clinical stabilization and provides sustained clinical benefits. Kunwar Shailubhai, Chief Executive Officer & Chief Scientific Officer of Tiziana commented, "We are very excited about the positive clinical data reported today demonstrating the potential of intranasally administered immunotherapy with foralumab for treatment of SPMS and other neurodegenerative diseases. Importantly, data from this patient serve as the first validation of our breakthrough and potentially transformational approach with a convenient, intranasal 'take home' immunotherapy for SPMS and other neurological diseases. Today's news marks an important first step toward advancing our platform using alternative, novel routes of immunotherapies to provide local rather than systemic delivery of antibodies." Foralumab was given to an SPMS patient intranasally into each nostril on a regimen of M-W-F for two weeks followed by one week off therapy for a period of six months. This regimen was well-tolerated with associated beneficial clinical and biomarker changes. Consistent with clinical and PET observations, intranasally administered foralumab also downregulated serum levels of pro-inflammatory cytokines. Clinical evaluation showed improvement in Timed 25-Foot Walk Test, 9-Hole Peg Test and Symbol Digit Modality Test. Other published PET studies have shown an increase in activated microglial cells in patients with secondary progressive MS, and the increase in AMCs associated with higher scores on the Expanded Disability Status Scale , a widely-used scale to measure disability

07:23 EST Natera has not misstated accuracy of NIPT to investors, says CEO

07:21 EST Passage Bio doses first patient in trial for infantile Krabbe disease - Passage Bio announced that the first patient with early infantile Krabbe disease has received PBKR03, an adeno-associated virus-delivery gene therapy, in its global Phase 1/2 clinical trial, GALax-C. "It is gratifying to dose the first patient in our GALax-C trial," said Bruce Goldsmith, Ph.D., president and chief executive officer of Passage Bio. "We now have two global clinical trials with patients dosed under way. The advancement of these two clinical trials represents significant progress for our company in our mission to develop transformative medicines for people with devastating CNS disorders. We look forward to reporting initial safety and biomarker data from GALax-C by end of 2022."

07:18 EST Embark Trucks announces revised Q4, FY21 conference call time - Embark Trucks announced that it will release its financial results for the fourth quarter 2021 after market close on March 17, 2021. In order to best accommodate analysts' and investors' ability to participate in the Company's and other transportation companies' conference calls, Embark will now host its fourth quarter 2021 earnings conference call on March 17, 2022 at 4:30 p.m.

07:18 EST Natera CEO: 'Notion that we double bill patients simply false'

07:16 EST Akouos appoints Aaron Tward as CSO - Akouos announced the appointment of Aaron Tward, M.D., Ph.D., as chief scientific officer. Dr. Tward was previously a member of the Akouos scientific advisory board since 2018. As chief scientific officer, he will lead the research team, and provide strategic scientific expertise to advance the company's precision genetic medicine platform to address a broad range of inner ear conditions. He has served as an associate professor of Otolaryngology - Head and Neck Surgery at the University of California, San Francisco.

07:15 EST First American appoints Paul Hurst as chief innovation officer - First American announced the appointment of Paul Hurst as chief innovation officer. Hurst will report to Ken DeGiorgio, chief executive officer of First American Financial Corporation.

07:14 EST Natera CEO: NYT article 'full of inaccuracies and misleading statements'

07:13 EST Natera would be in position to cease using MGML with miminal impact to business

07:12 EST Huntsman urges shareholders to vote on the WHITE proxy card - Huntsman announced that it has mailed a letter to shareholders in connection with its upcoming Annual Meeting of Stockholders scheduled for March 25, urging shareholders to vote the WHITE proxy card "FOR ALL" of Huntsman's highly qualified directors standing for election. Stockholders of record as of February 1, will be entitled to vote at the meeting.

07:11 EST Natera works with multiple groups, including MGML, says CEO - MGML "neither owned, operated nor controlled" by Natera, says Natera's CEO.

07:09 EST Natera strongly disagrees with Hindenburg's characterization of federal guidance

07:08 EST Galera Therapeutics provides update on clinical programs - Radiotherapy-Induced Toxicity Programs: Esophagitis: The Company expects to report topline data from the Phase 2a AESOP trial of avasopasem evaluating its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer in the first half of 2022. Anti-Cancer Programs: Locally Advanced Pancreatic Cancer: Enrollment is ongoing in the Phase 2b GRECO-2 trial of rucosopasem in combination with stereotactic body radiation therapy in patients with LAPC. Non-Small Cell Lung Cancer: Enrollment is ongoing in the Phase 1/2 GRECO-1 trial of rucosopasem in combination with SBRT in patients with NSCLC. The Company expects to report initial data from this trial in the first half of 2022.

07:07 EST Galera Therapeutics expects cash to fund operations into H2 of 2023 - As of December 31, 2021, Galera had cash, cash equivalents and short-term investments of $71.2M. Galera expects that its existing cash, cash equivalents and short-term investments will enable Galera to fund its operating expenses and capital expenditure requirements into the second half of 2023.

07:06 EST Natera CEO: Disagree with characterization of services offered to physicians - Comments taken from conference call on the "misleading" short seller report.

07:05 EST Kraton announces price increases for HSBC polymers - Kraton announces a general price increase of 440 USD/MT for all Kraton HSBC polymers. This price increase is driven by recent significant cost increases in raw materials, energy and logistics costs. Given the unprecedented increases for natural gas costs in Europe, additional energy surcharges will be applied to HSBC polymers produced in our HSBC plant in Berre, France. Subject to the terms of any applicable contracts, these price increases and surcharges will take effect April 1.

07:04 EST ObsEva announces its 2022 anticipated milestones - ObsEva expects to achieve the following key clinical and regulatory objectives in 2022: Linzagolix for uterine fibroids: Prescription Drug User Fee Act target action date of September 13, 2022, as set by the U.S. Food and Drug Administration; European Commission approval expected following December 2021 positive Committee for Medicinal Products for Human Use opinion. Linzagolix for endometriosis: Additional data from the 6-month analysis are expected in 1Q:22. Additional data from the post-treatment follow-up of the Phase 3 EDELWEISS 3 trial are expected in 2Q:22 and from the post-treatment follow-up of the extension study in 4Q:22

07:02 EST Walmart to expand Baytown supply chain campus - Walmart announced plans to expand its Baytown, Texas supply chain campus with a new 1,000,000+ square-foot distribution center to support the retailer's growing supply chain network. The new facility, located at 4633 Borusan Road, is the retailer's fourth in Baytown and is set to open in the Fall of 2022, bringing the total square-footage of the campus to over 5,000,000 square-feet. The expansion will create an additional 300 full-time jobs due to growth across multiple shifts.

06:54 EST Velodyne Lidar selected by Russelsheim am Main for Infrastructure Solution - Velodyne Lidar announced that the city of Russelsheim am Main, Germany, has selected Velodyne to deliver an Intelligent Infrastructure Solution to create a city-wide system for truck passage control. Russelsheim will use Velodyne's lidar-based full stack solution for digital monitoring and reporting of trucks that are banned on city streets to ease road congestion and air and noise pollution. As part of an initiative to digitize municipal transport systems, Russelsheim will deploy Velodyne's Intelligent Infrastructure Solution using 16 lidar-based monitoring stations located on heavily traveled access roads used for entering and exiting the city.

06:48 EST Lazard reports preliminary AUM approximately $251.6B as of February 28 - Lazard reported that its preliminary assets under management as of February 28 totaled approximately $251.6B. The month's AUM included market depreciation of $5.3B, net outflows of $2.1B and foreign exchange appreciation of $0.3B.

06:45 EST EHang receives pre-order for 60 units of AAVs from Malaysian aviation company - EHang announced its strategic partnership with Aerotree Flight Services, a subsidiary of Malaysia's leading aviation company Aerotree Group, to jointly develop urban air mobility business, including Maintenance, Repair and Overhaul and training, in Malaysia. Pursuant to the Partnership, Aerotree has placed the largest pre-order for EHang's electric passenger-grade AAVs in Malaysia for 50 units of the EH216 series, which includes the EH216-S1, EH216-L, and EH216-F, as well as 10 units of the VT-30, EHang's long-range eVTOL. Prior to it, AEROTREE has purchased one unit of the EH216-S AAV from EHang.

06:38 EST ViewRay announces toxicity results from SCIMITAR trial - ViewRay announced the first toxicity results from the prospective single-arm Phase II SCIMITAR trial. A secondary analysis compared the findings of treatment under CT-guidance to MRI-guidance and found that patients treated with MRI-guidance had a 30.5% reduction in any grade acute GI toxicity and a 32% reduction in any grade cumulative GI toxicity up to six months. No patient treated with MRI-guided radiation therapy experienced any grade 3 GU or GI toxicity. Surgery, known as prostatectomy, is a common treatment for prostate cancer and it is estimated that up to 1/3 of patients will experience some recurrence of their cancer within 10 years after their prostatectomy. The current standard treatment for most patients with recurrent prostate cancer after surgery is up to 7-8 weeks of radiation therapy. UCLA is at the forefront of studying SBRT for intact prostate, recently announcing interim data from their single center Phase III randomized MIRAGE trial, which signaled superiority of MRI-guided SBRT over CT-guided SBRT for localized prostate cancer. Five fraction SBRT in the post-prostatectomy setting is currently only possible within a clinical trial, and the prospective Phase II "StereotaCtic Intensity Modulated RadIoTherapy After Radical Prostatectomy" trial led by UCLA is examining the safety and efficacy of postoperative SBRT at a dose of 30-34 Gy in five fractions. The first toxicity results from the trial, which will be presented at ACRO 2022, evaluated 100 patients with recurrent prostate cancer after radical prostatectomy. The patients underwent SBRT delivered under either CT guidance or MRI guidance. Acute and late genitourinary and gastrointestinal toxicity were evaluated based on the Common Terminology Criteria for Adverse Events. Patient-reported toxicity outcomes were based on Expanded Prostate Cancer Index-26 instrument and International Prostate Symptom Scores. SBRT after prostatectomy was feasible, with a favorable overall toxicity profile both in clinician-scored and patient-reported outcome measurements. However, the post-hoc analysis signaled that MRI-guided radiation therapy may be associated with reduced acute physician-scored GI toxicity.

06:34 EST DTE Energy Chairman Gerry Anderson to retire, Jerry Norcia to succeed - DTE Energy Executive Chairman Gerry Anderson will retire on June 30 after a 29-year career with the company. Current DTE President and CEO Jerry Norcia will assume the additional role of chairman of the board effective upon the expiration of Anderson's current term on May 5.

06:14 EST General Electric: Power business on track for stable earnings, cash generation

06:05 EST Landsea Homes sees 2022 new home deliveries 490-520 - Sees 2022 delivery ASPs $460K-$470K.

06:02 EST ChipMOS reports February revenue $74.8M, up 7.1% - The company said. "Revenue for the month of February 2022 was NT$2,096.9 million or US$74.8 million, an increase of 7.1% compared to February 2021 and a decrease of 7.7% compared to January 2022. The record high February 2022 revenue level reflects continued favorable supply and demand dynamics, and the benefit of stable higher utilization level across its DDIC high-end test platform."